Interestingly, it has been recently reported that the novel anti-CXCR4 antibody ulocuplumab shows an anti-LPL/WM activity by inhibiting tumor growth both in in vitro and in vivo studies [147]. The gene discussed is CXCR4; the disease is neoplasm.